|
TDRD3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.81970000179277E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.29419999851078E-08 |
| Normal-vs-Stage2 |
2.921700E-03 |
| Normal-vs-Stage3 |
8.90760021299286E-10 |
| Normal-vs-Stage4 |
2.06520000000099E-05 |
| Stage1-vs-Stage2 |
2.428200E-01 |
| Stage1-vs-Stage3 |
5.999700E-02 |
| Stage1-vs-Stage4 |
9.821400E-01 |
| Stage2-vs-Stage3 |
2.385800E-02 |
| Stage2-vs-Stage4 |
3.763400E-01 |
| Stage3-vs-Stage4 |
1.855190E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.26099966211302E-10 |
| Normal-vs-AfricanAmerican |
1.174050E-02 |
| Normal-vs-Asian |
2.15499999999258E-05 |
| Caucasian-vs-AfricanAmerican |
1.882640E-01 |
| Caucasian-vs-Asian |
1.977600E-01 |
| AfricanAmerican-vs-Asian |
5.950800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.87453999999088E-05 |
| Normal-vs-Female |
2.19249995936366E-09 |
| Male-vs-Female |
5.429600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.07890000161848E-08 |
| Normal-vs-Age(41-60Yrs) |
1.23079999525544E-08 |
| Normal-vs-Age(61-80Yrs) |
1.45839999998731E-06 |
| Normal-vs-Age(81-100Yrs) |
2.676400E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.613800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.393000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.627200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.823800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.205800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.587400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.558700E-03 |
| Classical-VS-Follicular |
6.138800E-01 |
| Classical-VS-Other |
6.719600E-01 |
| Classical-VS-Normal |
5.68080000040716E-07 |
| Tall-VS-Follicular |
3.781900E-02 |
| Tall-VS-Other |
7.458000E-02 |
| Tall-VS-Normal |
4.80319994888845E-09 |
| Follicular-VS-Other |
5.754200E-01 |
| Follicular-VS-Normal |
3.23650000000342E-06 |
| Other-VS-Normal |
9.164400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.40939999671019E-08 |
| Normal-vs-N1 |
2.44670000038028E-07 |
| N0-vs-N1 |
5.015000E-01 |
|
|
